LucenceINSIGHT Multi-Cancer Early Screening
Liquid biopsy technology designed for a proactive, early detection strategy and timely treatment.
What is LucenceINSIGHT multi-cancer early screening?
LucenceINSIGHT is an early detection tool that screens for signs of up to 50 different cancers using a simple blood test. This ranges from commonly occurring cancers, such as colon and breast cancer to more uncommon ones, such as acute myeloid leukaemia and eye cancer.
By harnessing the power of advanced genomics, and artificial intelligence, it can detect cancer at its earliest stages. Additionally, it can also predict the location of these cancer biomarkers through its advanced sequencing analysis, thereby prompting timely intervention and treatment.
Up to 50 Cancers Screened, 1 Draw of Blood
How does LucenceINSIGHT multi-cancer early screening work?
Through a simple blood draw, the blood test detects cancer by analysing the DNA particles that are shed by tumours into the bloodstream. Additionally, with the use of advanced genomics technology, a specialised computer is then used to help identify genetic changes linked to cancer. It can also analyse the type, and stage of cancer, which ultimately aids doctors in outlining a more personalised treatment plan, apart from diagnosing, and monitoring cancer earlier, and more accurately.
Benefits of LucenceINSIGHT multi-cancer early screening
Some of the benefits of LucenceINSIGHT multi-cancer early screening are:
- Accuracy: the test offers a sensitivity of 80.9% and specificity 99%.
- Comprehensive: the test detects up to 50 types of cancer, including breast, colon, prostate, and lung.
- Early detection: the test detects cancer before symptoms begin to present themselves, thereby improving the treatment outcomes.
- Non-invasive: the test works via a simple blood draw and requires no biopsy or surgical probe.
What’s the difference between the LucenceINSIGHT multi-cancer screening and regular tumour marker blood tests?
| LucenceINSIGHT Multi-Cancer Screening | Standard Tumour Marker Blood Tests | |
| Medical Approach | Designed for early detection across 50 types of cancer for proactive, early detection. | Standard tumour marker tests look for higher levels of specific proteins produced by cancer cells. These are usually picked up after the onset of symptoms. |
| Detection Scope | Broad scope approach that analyses several DNA mutations and methylation patterns in blood. | Detects a narrower scope of cancers using protein-based tumour markers. |
| Technology and Precision | Utilises liquid biopsy and genomic profiling, or genetic alterations or abnormalities that can indicate early cancer changes. | Measures protein levels in blood that can change due to cancerous conditions. |
| Application | Useful for proactive, early cancer screening. | Useful for detecting specific types of cancer when you experience specific symptoms or have a known family history of cancer. |
| Cost and Accessibility | More costly due to the complex technology and comprehensive screening. | More widely available and generally less expensive. |
| Specificity (ability to rule out when cancer is not present) | 99% (virtually 0% false positives) | About 60% (up to 40% false positives) |
| Sensitivity (ability to detect cancer when present) | 80.9% | Varies, generally depends on the specific type of tumour marker test |
One of the most remarkable benefits of the LucenceINSIGHT multi-cancer tests is its virtually zero false positive rate, with a specificity of 99% — accurately ruling out cancer when it’s not present. In contrast, traditional tumour marker tests have a high false positive rate of about 40%, often leading to unnecessary anxiety, further testing and additional costs.
LucenceINSIGHT tests offer an 81% sensitivity, meaning they can detect cancers 81% of the time, greatly reducing the risk of a missed diagnosis, especially in the early stages.
When is LucenceINSIGHT multi-cancer early screening recommended?
LucenceINSIGHT is often recommended as an additional test on top of existing screening tools, such as an ultrasound for prostate cancer. It is also recommended when patients are presented with risk factors that increase their likelihood of developing cancer;
- Age: the test is recommended for individuals aged 40 years old or older.
- Family history: individuals with a family history of cancer are recommended to undergo the screening test.
- Diet: individuals who consume a high-fat, low-fibre diet are encouraged to undergo the screening test as the diet has been linked with an increased risk of cancer, especially bowel, and prostate cancer.
- Health history: the test is highly recommended for individuals who have had a history of viral infections such as Human papillomavirus (HPV) and Epstein-Barr virus (EBV). Additionally, LucenseINSIGHT is also warranted for individuals with predisposing conditions such as Type II diabetes.
- Lifestyle: individuals who smoke, consume alcohol excessively, or barely engage in physical activity are encouraged to undergo this screening test.
With that said, because of its precision and sensitivity, LucenceINSIGHT is an excellent option for those seeking proactive, early detection among multiple cancer types — allowing for timely intervention and optimal outcomes. A consultation with our doctor will help determine your suitability for the test.
Why is early cancer screening important?
Globally, approximately 19 million new cases are recorded annually, with half of the cases resulting in late-stage deaths. In Singapore, cancer is the number one cause of death, and Singapore’s ageing population further increases the prevalence of cancer. Beyond that, approximately 78% of cancer deaths are from unscreened cancers such as liver, stomach, pancreas, and nasopharyngeal cancer.
Between 2017, and 2021, an average of 46 individuals were diagnosed with cancer, and 16 individuals lost their lives to cancer daily in Singapore. Additionally, 1 in 4 people is at risk of developing cancer in their lifetime due to a multitude of factors, such as genetics, and lifestyle. With such a high prevalence, early detection, and intervention are key to a more positive treatment outcome.
Additionally, early cancer screening can also help to:
- Increasing recovery chances.
- Increasing optimal survival odds (the survival rate is increased by 4 times with early diagnosis).
- Lowering medical costs (the more advanced the cancer is, the higher the medical bills).
- Minimise cancer-related complications.
- Preventing cancer from progressing to advanced stages.
What results can I expect from LucenceINSIGHT multi-cancer early screening?
Depending on the results, your next course of action would entail:
Positive results
- A positive result indicates that cancer biomarkers are present.
- The result will also highlight possible localisation areas, indicating where the abnormalities originate from.
- Our doctor will recommend further diagnostic tests to reach a definitive diagnosis.
Negative results
- A negative result indicates that cancer biomarkers are absent.
- However, the result does not disregard the possibility of cancer.
- Keep in mind that the test screens for 50 types of cancer, and not all types of cancer.
- Our doctor will recommend routine screening as a preventive measure.
How many sessions are typically recommended?
Similar to health screenings, it is recommended to schedule cancer screenings annually, or biannually. However, when it comes to cancer screening, the frequency will depend on your doctor’s discretion as it involves several factors such as type of cancer, stage, family history, and current health conditions.
If you are interested in scheduling an early cancer screening for yourself or your loved ones, then wait no more. Contact us today to book a slot, and speak with our doctors to stay a step ahead of this disease.
Frequently asked questions
How accurate are the results from the LucenceINSIGHT multi-cancer early screening?
The LucenceINSIGHT multi-cancer early screening test offers an accuracy of about 80.9%.
How does the LucenceINSIGHT multi-cancer early screening differ from conventional screening tests?
The major difference between LucenceINSIGHT and conventional screening tests is that conventional tumour marker tests generally measure proteins in the blood that are elevated to indicate the possible presence of cancer. On the other hand, LucenceINSIGHT analyses DNA and detects genetic mutations that may indicate cancer. This allows it to detect cancers early, even before measurable levels of tumour proteins are produced.
Are there any risks associated with the LucenceINSIGHT multi-cancer early screening that I should be aware of?
While there are no risks associated with the screening test, it is important to understand that the test is designed to screen for cancer, and not to diagnose it.
How soon will I obtain my results?
It takes approximately 12 to 18 days for you to receive your results. Once our doctors have received your results, our administrative staff will call you to schedule a consultation appointment, where our doctors will analyse, and explain the results to you.